在使用促黄体生成素释放激素激动剂（诺雷德）治疗绝经后晚期乳腺癌期间出现的反应。
A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex.
作者信息
Cassano A, Astone A, Garufi C, Noviello M R, Pietrantonio F, Barone C
机构信息
Istituto di Clinica Medica, Università Cattolica del Sacro Cuore, Rome, Italy.
出版信息
Cancer Lett. 1989 Nov 30;48(2):123-4. doi: 10.1016/0304-3835(89)90047-5.
Luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in pre-menopausal women. Clinical responses are attributed to the suppression of the pituitary-ovarian axis, with a reduction in circulating levels of gonadal steroids similar to that produced by castration. In the present case report, we report a partial response to a LHRH analogue in a post-menopausal woman refractory to other endocrine treatments. This response cannot be explained with a chemical castration and confirms the possible direct anti-tumor effect of Zoladex.
促黄体生成激素释放激素（LHRH）激动剂目前正在进行临床试验，用于治疗绝经前女性的晚期乳腺癌。临床反应归因于垂体-卵巢轴的抑制，性腺类固醇的循环水平降低，类似于去势所产生的效果。在本病例报告中，我们报告了一名绝经后女性对LHRH类似物产生部分反应，该女性对其他内分泌治疗无效。这种反应无法用化学去势来解释，并证实了诺雷德可能具有直接抗肿瘤作用。
Zotero 插件